No Data
Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Maintains Target Price $105
Mixed Efficacy and Safety Profiles Lead to Hold Rating for Blueprint Medicines and Cogent Biosciences
Unusual Options Activity: MSFT, SATS and Others Attract Market Bets, MSFT V/OI Ratio Reaches 90.2
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report
A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $105 to $135
Wells Fargo Maintains Overweight on Blueprint Medicines, Lowers Price Target to $151
No Data
No Data
